Stay updated on Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.

Latest updates to the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe Publications section now notes that entries are automatically filled from PubMed and may not all relate to the study. The page revision indicates Revision: v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedThe page removed the notice about government funding and operating status. This does not affect the study details or participation information.SummaryDifference0.4%

- Check42 days agoChange DetectedNo significant additions or deletions were observed on the Study Details page for NCT03066258; the critical study information, eligibility criteria, locations, and timelines remain unchanged.SummaryDifference0.4%

- Check71 days agoChange DetectedSignificant update: new operating-status notice and funding-related limitations are added, plus a version bump to v3.2.0; previous v3.1.0 deletion indicates a version upgrade.SummaryDifference4%

- Check78 days agoChange DetectedVersion metadata updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2, indicating a minor revision. The Back to Top element was removed; no other substantive content changes were detected.SummaryDifference0.2%

Stay in the know with updates to Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.